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Abstract
Objective To determine the trend in the association between
socioeconomic status and sex and median age at death from cystic
fibrosis in England and Wales, over the past 50 years.
Design Series of annual cross sectional studies of all registered deaths
with a diagnosis of cystic fibrosis in England and Wales, from 1959 to
2008.
Methods We obtained national mortality data for cystic fibrosis from the
Office for National Statistics. From 1959 to 2000, the Registrar General’s
Social Class coded socioeconomic status as manual or non-manual.
From 2001 onwards, the National Statistics Socioeconomic Classification
was implemented and socioeconomic status was split into three groups:
professional and managerial, intermediate, and routine and manual. We
calculated median age at death for every study year. We calculated the
effects of sex and socioeconomic status on the odds of death above the
median age at death for every study decade using logistic regression.
Results From 1959 to 2008, 6750 deaths were attributed to cystic fibrosis
in England and Wales. Males were more likely to die above the annual
median age at death than females (from 1959 to 1999, adjusted odds
ratio for socioeconomic status 1.28, 95% confidence intervals 1.13 to
1.45; from 2000 to 2008, 1.57, 1.18 to 2.08). Individuals in the highest
socioeconomic class were also more likely to die above the median age
of death than those in the lowest socioeconomic class (from 1959 to
2000, adjusted odds ratio for sex 2.50, 2.16 to 2.90; from 2001 to 2008,
1.89, 1.20 to 2.97).
Conclusions Socioeconomic status and sex remain strong determinants
of survival from cystic fibrosis in England and Wales, and the magnitude
of these effects does not appear to have substantially reduced over time.
Introduction
Over the past 50 years, survival in individuals with cystic
fibrosis has improved greatly, with the median age at death
rising from 6 months in 1959
1 to 27 years in 2008.
2 For
individuals with cystic fibrosis born in 2000, the median age of
survival is predicted to approach 50 years.
3-5 Improved survival
has been attributed to multiple factors including early
diagnosis,
6 7 improvements in nutrition,
8 infection control,
9-11
nebulised mucolytics,
12 and antibiotic treatment.
13 14 Factors
associated with early death include the δF508 mutation,
15
pancreatic insufficiency,
16 17 low body mass index,
18 early
acquisitionofPseudomonasaeruginosa,
19-21lowsocioeconomic
status,
1 22 23 and female sex.
24-27
High socioeconomic status was identified as a marker of good
prognosis in cystic fibrosis over 20 years ago, when children
with cystic fibrosis from manual socioeconomic groups in
England and Wales were found to be nearly three times more
likely to die below the annual median age at death than those
from non-manual socioeconomic groups.
1 Schechter and
colleagues reported a similar effect in Medicaid patients in the
United States,
22 and other reports have shown reduced survival
in patients living in postal code areas with below median
incomes.
23
The association between female sex and impaired prognosis in
cystic fibrosis has also been well described,
24 25 with a median
differenceof3.1yearsinonestudy.
26ACanadianstudyreported
thatfemaleshadmorethantwicethetwoyearriskofdeaththan
their male counterparts.
27 Other studies have reported poorer
survival in females than in males in the United States
24 and the
United Kingdom.
28
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RESEARCHThe past 20 years have seen considerable improvements in
healthcare provision, including improvements in antibiotic and
nutritiontreatment,andtheuseofmultidisciplinaryapproaches
to management with the formation of specialist treatment
centres. We postulated that improvements in healthcare
provision will weaken the effect of socioeconomic status and
sex on median age at death from cystic fibrosis.
Methods
We obtained mortality data for cystic fibrosis for England and
Wales for 1959 to 2008 from the Office for National Statistics.
We used the International Classification of Diseases (ICD)
applying to cystic fibrosis to code cause of death. The ICD-9
category for cystic fibrosis was 587.2 in 1959-67,
29 273 in
1968-78,
30 and 277 in 1979-2000.
31 On publication of ICD-10
in 2001, the category for cystic fibrosis changed to E84.
32
We classified socioeconomic status using a combination of
occupation and employment status. From 1959 to 2000, the
Registrar General’s Social Class coded socioeconomic status
as manual or non-manual.
33 From 2001, the National Statistics
Socioeconomic Classification
34 classification was used and
social class was split into three groups: professional and
managerial, intermediate, and routine and manual. For deaths
recorded in 1959-78, married women were coded by their
husband’ssocioeconomicclass.Fordeathsrecordedfrom1979,
married women were coded by their own occupation; however,
ifthiswasunclassified,theirhusband’soccupationwouldapply.
Throughoutthestudyperiod,unmarriedandsinglewomenwere
coded by their own socioeconomic class when available.
Childrenyoungerthan16yearswereclassifiedbytheirfather’s
occupation and if their father was not classified, by their
mother’s occupation. Socioeconomic status for adults was
unclassified if individuals were permanently sick, long term
unemployed, had never worked, or were in full time education,
or if occupation was not stated or described adequately.
To protect anonymity, age at death for each individual was
provided by the Office for National Statistics within a five year
age range. We estimated age at death as the midpoint of the
correspondingfiveyearageband;ageatdeathwasnotnormally
distributedforanystudyyear.Weestimatedmedianageatdeath
foreverystudyyear,andcategorisedindividualdeathsaseither
above or not above the median age for a particular study year.
Data were stratified into decades to allow sufficient numbers
forstatisticalcomparisons.Weincludeddeathsrecordedin1959
in the 1960-69 analysis. Owing to the implementation of the
National Statistics Socioeconomic Classification in 2001, we
combineddeathsin2000withdeathsin1990-99forsocialclass
analysis only. Deaths recorded between 1964 and 1969 did not
include any socioeconomic data, and we therefore excluded
these study years from socioeconomic class analysis.
We calculated the effects of sex and socioeconomic status on
the odds ratio for death above the median age at death for every
decade by logistic regression using Stata 11 statistical software
(Texas, USA). Since both sex and socioeconomic status were
associated with the outcome, we mutually adjusted models.
Results
Between 1959 and 2008, 6750 deaths recorded in England and
Wales were attributed to cystic fibrosis. The number of deaths
per study year fell during the study period, with a maximum of
214 in 1960 and a minimum of 91 in 2006 (fig 1⇓).
Medianageatdeathincreasedfromageband0-4yearsto25-29
years between 1959 and 2008 (fig 2⇓). From the mid-1970s,
medianageatdeathtendedtobehigherinmalesthaninfemales
(fig3⇓).Afterweadjustedoddsratiosforsocioeconomicstatus,
males were more likely to die above the median age at death
than females in the 1970s and 1980s (table 1⇓). Overall, the
adjusted odds ratio was 1.28 (95% confidence intervals 1.13 to
1.45) from 1959 to 1999, and 1.57 (1.18 to 2.08) from 2000 to
2008. Between 2000 and 2008, median age at death was also
significantly higher in men (age band 25-29 years) than in
women (20-24 years).
Of the 4886 deaths with available social class data between
1959 and 2000, occupation was classified as manual in 2112
(43%)individuals,non-manualin1391(29%),andunclassified
in 1383 (28%). Median age at death was higher in the
non-manual group than in the manual group for most study
years between 1959 and 2000, and these differences were
particularly apparent in the late 1980s and early 1990s (fig 4⇓).
Odds ratios for death above median age at death were
significantly lower in the manual group than in the non-manual
group at all study time points (table 2⇓).
For the 873 deaths between 2001 and 2008, socioeconomic
status was coded as professional and managerial in 143 (16%)
individuals, intermediate in 113 (13%), routine and manual in
175 (20%), and unclassified in 442 (51%).
After adjusting odds ratios for sex, we found that individuals
in the highest socioeconomic class were also more likely to die
above the median age of death than those in the lowest
socioeconomicclass(from1959to2000,2.50,95%confidence
intervals 2.16 to 2.90; from 2001 to 2008, 1.89, 1.20 to 2.97)
(fig4)(table2).Medianageatdeathdidnotdiffersignificantly
between the intermediate group and the routine and manual
group (table 2). From 2001 to 2008, median age at death was
lower in the unclassified group than in the routine and manual
group (table 2).
Discussion
In this cross sectional study of all registered deaths from cystic
fibrosis in England and Wales, our data show that the median
ageatdeathhasincreasedfrom0-4yearsin1959to25-29years
in2008,andthatsocioeconomicstatusandsexremainimportant
risk factors for age at death. In addition, despite the overall
increase in median age at death from cystic fibrosis, our data
consistently show that individuals classified in the highest
socioeconomic group are more likely to die at an older age than
those in the lowest socioeconomic group. This trend did not
changethroughoutthe50yearstudyperiod.Furthermore,health
inequalities were not confined to the lowest socioeconomic
group. From 2001 to 2008, median age at death in the
intermediate socioeconomic group was comparable to that of
the lowest group, with the highest group having a survival
advantage.Femaledisadvantagepersistedintothe21stcentury,
with females having a higher risk of death below the median
age of death than males.
Limitations
The findings of this study depend on the accuracy of the initial
diagnosisofcysticfibrosisandsatisfactorycompletionofdeath
certificatesincludingthedocumentationofadiagnosisofcystic
fibrosis. The extent of under-diagnosis of cystic fibrosis in the
early years of this study is not clear. In addition, improved
diagnostictechniqueshaveledtoincreasedrecognitionofmilder
phenotypes which will affect the outcome variable measured.
From1959to1967,theInternationalClassificationofDiseases
category applying to cystic fibrosis included other disease of
the pancreas and might therefore include deaths without a
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29 However, we have previously
estimatedthatlessthan2%ofdeathsareprobablymisclassified
in this way, and this proportion is therefore unlikely to affect
the overall findings of our study.
1 The consistency of the
associations observed supports this estimate. Furthermore,
improved diagnostic techniques in the later study years may
have enhanced the recognition of mild phenotypes of cystic
fibrosis, which could have contributed to the increased rate of
survivalobserved,althoughthisfactorprobablydoesnotaccount
for the differences in sex or socioeconomic status.
Due to confidentiality constraints, we used age at death as the
midpoint of every five year age band, which could have
underestimated the association between socioeconomic status
and sex with median age at death. The use of the median age
of death was necessary for statistical comparisons between
groups,butthisisabroadsummarystatisticthatwillnotreflect
a wide spread in ages at death within each year. The data
available to us did not provide sufficient power to compare the
interactionbystudydecadeofdeathontheassociationbetween
age of death and socioeconomic status or sex. However, the
similar odds ratios with overlying confidence intervals for the
first and last study decades indicate that the magnitude of these
associations does not appear to have reduced substantially over
time.
Wedefinedsocioeconomicstatusaccordingtooccupationfrom
1959 to 2000 using the Registrar General’s Social Class. In
2001, implementation of the internationally recognised and
validated
35 National Statistics Socioeconomic Classification
made longitudinal trend comparisons difficult. The availability
of socioeconomic status data also varied throughout the study
period, with over half of deaths (51%) between 2001 and 2008
coded as unclassified, compared with 28% between 1959 and
2000 (when socioeconomic data were available). Since the
definition of unclassified socioeconomic status encompasses a
broad cross section of society, such as those adults who were
permanently sick, were in long term unemployment, or had
never worked to adults in full time education, this represents a
limitation of our data.
Wesawanincreasedriskofdeathabovetheannualmedianage
of death for the unclassified socioeconomic group from 1959
to 1989; after this time the risk decreased, suggesting that the
composition of this group changed over the past half century
and possibly reflecting societal change. However, we do not
consider that this finding changes the validity of our
comparisons between those individuals who could be allocated
to a defined social category. We have presented the raw data in
two ways, as graphical representations of the annual data and
asstatisticalcomparisonsofsurvivalbysexandsocioeconomic
statususingdataroughlystratifiedindecadestopermitsufficient
numbers for comparison. The annual data can show trends over
time, although relatively small numbers of events per year
prevent conclusions being drawn over short periods of time.
Finally, owing to improved survival, the lag time between the
implementation of healthcare changes and median age at death
is inevitably increasing. Consequently, these results reflect
historical healthcare management, and the results of current
healthcare strategies, particularly those aimed at younger
patients, will not have filtered into the mortality figures yet.
Sex
Moststudieshaveshownthatfemalesareassociatedwithworse
outcomes than their male counterparts.
24 25 27 28 However, the
cause of the sex gap remains unclear. Several studies suggest
thatfemalepreponderanceforearlyacquisitionofPaeruginosa
might have a role.
20 26 Demko and colleagues
20 showed that
females became infected with chronic mucoid P aeruginosa an
average of 1.7 years earlier than their male counterparts. Other
studies have suggested that increased occurrence of cystic
fibrosis-relateddiabetes,
36reducedactivitylevels,
37poormental
health,
38 poor nutritional status,
27 and oestrogens
39 40 could
contribute to the difference between males and females.
Socioeconomic status
The association between poor socioeconomic status and
increased mortality in individuals with a diagnosis of cystic
fibrosis is well established.
1 22 23 These socioeconomic health
disparities have been shown in both the universal healthcare
system in the United Kingdom and the predominantly private
based care system in the United States. In 1998, Schechter and
colleagues
41 reported that Medicaid patients (a marker of low
incomeintheUnitedStates)hadworselungfunctionandlower
body mass index and required more hospital admissions than
their socioeconomically advantaged counterparts. In 2008,
Balmer and colleagues
42 found that socioeconomically
disadvantaged children with cystic fibrosis in the United States
had poorer growth, lower lung function, and more days off
school than socioeconomically advantaged children. However,
thecauseofthissocioeconomichealthgapispoorlyunderstood.
Low socioeconomic status has been associated with increased
environmental exposure to tobacco smoke,
43 inadequate
nutrition,
22 little understanding of the underlying disease,
44 45
and poor treatment adherence.
41
It is difficult to determine what role these individual factors
have because social class is a composite measure that
incorporates income, education, and occupation. It is clear,
however,thatsocioeconomicstatusmayaffectchildhoodhealth
from an early age. Phenotypical differences between high and
low socioeconomic groups have been found in children with
cystic fibrosis as young as 6 years, and these disparities persist
intoadulthood.
23 41However,reversecausationcouldcomplicate
theassociationbetweenlowsocioeconomicstatusandincreased
mortality. Individuals with cystic fibrosis are more likely to
leave school without any qualifications than the general
population and therefore less likely to have professional
occupations,andthisdifferenceisincreasedinindividualswith
severeunderlyingdisease.
46Conversely,individualswithcystic
fibrosis who are in employment are more likely to have
non-manual occupations than the general population,
46 perhaps
because they are less able to fulfil more physically demanding
work.Sinceourdatafromrecentyearscoverdeathsinamainly
adult population, we cannot exclude the possibility that these
factors might contribute to our observations of differences in
mortality between socioeconomic groups.
Provision of care
Over the past few decades, increasing awareness of the
complexityofcysticfibrosisdiseasemanagementhasledtothe
formation of specialist centralised centres. Specialist treatment
centres are widely considered to provide the best standard care
for patients
13 47 48 and are endorsed by regulatory bodies in the
United Kingdom,
49 50 United States,
51 52 and Australia.
53
Consequently, the proportion of patients accessing specialist
care has risen over the past 20 years.
54 55 However, direct
evidence supporting improved clinical outcomes in specialist
cystic fibrosis centres is limited and most studies have been
confoundedbysamplesize
6 56 57orbycomparisonwithhistorical
controls.
58 Mahadeva and colleagues
47 reported that patients
who attended specialist centres in Manchester had higher body
mass indexes, higher chest radiograph scores, and better
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receive any centralised care. However, direct comparisons
betweendifferentregionsmaybeconfoundedbyenvironmental
factors
59 and socioeconomic status.
1
Inequalities in access to specialist cystic fibrosis services have
shown marked regional variations.
4 Patients receiving care at
specialist centres generally travel further than those attending
local clinics and, although not a universal finding,
23 41 60 some
studies have shown that socioeconomically disadvantaged
individuals have limited access to specialist care, particularly
to adult services,
4 61 in the United Kingdom. Accordingly, the
proportion of patients from socioeconomically advantaged
backgrounds is over-represented at some specialist centres.
61
A possible interpretation of our data is that new specialist
treatment centres in the United Kingdom might have been
preferentially accessed by individuals with the highest
socioeconomic status, which could account for some of the
socioeconomicdiscrepancyseenduringthelate1980sandearly
1990s. Alternatively, the highest socioeconomic groups could
be better informed and hence obtain better healthcare when
attendingclinic.TheobservationbySchechterandcolleagues
60
that children living in affluent areas or with well educated
mothers were more likely to receive macrolides in 2004, one
year after a landmark study was published,
62 would support the
latter hypothesis. Our data also showed that individuals in the
unclassified socioeconomic group had a poorer outcome than
any other category over the past two decades. This
heterogeneous category included individuals who were
permanentlysick,longtermunemployed,orreceivingincapacity
benefits. The severity of the underlying disease and reverse
causation could have been contributing factors. However, this
category might represent the lowest socioeconomic group in
society, including individuals who struggle to access timely
healthcare.
Summary
We report nationally representative data that suggest that the
socioeconomic and sex differences in age at death from cystic
fibrosis that we first reported in 1989 persist to the present day,
in the context of a large improvement in survival in this patient
group over the past half century. Healthcare workers should be
awarethatfemalesandlowsocioeconomicstatusareassociated
withpooreroutcomesthanmalesandhighsocioeconomicstatus.
Environmental factors or varying access to healthcare might
account for some of these differences.
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RESEARCHTables
Table 1| Association of sex with risk of death at age greater than median age at death from cystic fibrosis in England and Wales, 1959-2008
Male deaths at age greater than median age at death
Female deaths (odds ratio) Total number of deaths Study year Adjusted* odds ratio (95% CI) Unadjusted odds ratio (95% CI)
0.99 (0.74 to 1.33) 1.05 (0.87 to 1.27) 1.00 1960 1959-69
1.55 (1.22 to 1.97) 1.48 (1.19 to 1.84) 1.00 1425 1970-79
1.35 (1.06 to 1.72) 1.31 (1.04 to 1.65) 1.00 1215 1980-89
1.25 (0.98 to 1.60) 1.19 (0.94 to 1.51) 1.00 1172 1990-99
1.57 (1.18 to 2.08) 1.44 (1.10 to 1.87) 1.00 978 2000-08
95% CI=95% confidence intervals.
*Adjusted for socioeconomic status.
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RESEARCHTable 2 | Association of socioeconomic status with risk of death at age greater than median age at death from cystic fibrosis in England
and Wales, 1959-2008
Risk of death at age greater than median age at death, by socioeconomic status
Total
number of
deaths Study year Unclassified*
Professional and
managerial* Intermediate*
Routine and
manual Unclassified* Non-manual* Manual
– – – – 3.55 (2.36 to 5.33) 1.90 (1.35 to 2.67) 1.00 969 1959-63†
– – – – 11.33 (8.24 to 15.58) 2.05 (1.57 to 2.69) 1.00 1425 1970-79
– – – – 3.39 (2.52 to 4.56) 3.04 (2.26 to 4.10) 1.00 1215 1980-89
– – – – 0.56 (0.41 to 0.76) 2.06 (1.52 to 2.80) 1.00 1277 1990-2000
0.30 (0.21 to
0.44) 1.89 (1.20 to 2.97)
1.07 (0.66 to
1.72) 1.00 – – – 873 2001-08‡
Data are odds ratio or adjusted odds ratio (95% confidence intervals) unless stated otherwise.
*Odds ratios adjusted for sex.
†Socioeconomic status not classified in 1964-69.
‡Socioeconomic status coding changed after 2000.
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Fig 1 Estimated number of deaths from cystic fibrosis in England and Wales, 1959-2008
Fig 2 Median age at death from cystic fibrosis in England and Wales, 1959-2008
Fig 3 Median age at death with diagnosis of cystic fibrosis by sex in England and Wales, 1959-2008
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RESEARCHFig 4 Median age at death with diagnosis of cystic fibrosis by socioeconomic status in England and Wales, 1959-2008
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